Reduction of epicardial adipose tissue thickness with PCSK9 inhibitors
Open accessAbstract
Abstract Introduction Epicardial adipose tissue (EAT) is clinically related to atherosclerosis and increased cardiovascular risk. The proprotein convertase subtilisin/kexin type 9 inhibitors (IPCSK9) are a novel group of effective drugs for lowering LDL cholesterol and cardiovascular events, however their effect on EAT has not yet been determined. Objective To assess the effect of treatment with PCSK9 inhibitors on epicardial adipose tissue. Methods The study enrolled 41 patients under treatment with PCSK9 inhibitors. At the end of the study only 24 patients were included, who were measured thickness of epicardial adipose tissue (TEAT) by transthoracic echocargiogram (just an echocardiographer using Siemens Acuson SC 2000 Prime with two-dimensional 4V1c transducer in two projections: long parasternal axis in the pericardial space of the outer edge of the myocardium above the right ventricle and in a short parasternal axis at the height of papillary muscles on the right ventricle, in telesystole and averaging three measurements; It was measured in millimeters.) using in 2 times before and after 6 months of initiation of treatment. Results Of 24 patients, 16 patients recieved evolocumab and 8 alirocumab patients; the mean TEAT pre-treatment and post-treatment was 6.84 mm (1.97) and 5.41 mm (1.86), respectively (p=0.0001); The mean percentage of change of the TEAT after 6 months of treatment was −20.39 (17.20). The mean serum LDL cholesterol levels pre-treatment and post-treatment were 188.04 mg/dL (144.0) and 94.96 mg/dL (106.04), respectively (p=0.0001); The mean change in LDL cholesterol was −51.89 (22.81). Just one patient had myocardial infarction. There was no difference between the means of reducing the percentage of change in epicardial adipose thickness between evolocumab and alirocumab. There was no correlation between lipid decrease and TEAT. Conclusion There is a significant reduction after 6 months of treatment with PSCK9 inhibitors in thickness of epicardial adipose tissue. Effect of IPCSK9 in TEAT and Lipids Funding Acknowledgement Type of funding source: None
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PCSK9 inhibitors reduce EAT thickness by 20% after 6 months.
“A study with pro-protein convertase subtilisin/kexin type 9 inhibitors, reports a remarkable 20% reduction in EAT thickness after 6 months of treatment [154].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review
Konwerski, M., Gąsecka, A., Opolski, G., Grabowski, M., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11030355 · Cited by 127 · see citing works
“showed a significant reduction in thickness of EAT after 6 months of treatment with other lipid-lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors [181].”
BackgroundEpicardial Adipose Tissue and Cardiac Arrhythmias: Focus on Atrial Fibrillation
Conte, M., Petraglia, L., Cabaro, S., Valerio, V., Poggio, P., Pilato, E., Attena, E., Russo, V., Ferro, A., Formisano, P., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.932262 · Cited by 115 · see citing works
Myasoedova, V. A., Parisi, V., Moschetta, D., Valerio, V., Conte, M., Massaiu, I., Bozzi, M., Celeste, F., Leosco, D., Iaccarino, G., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01738-2 · Cited by 93 · see citing works
“Interestingly, a recent type of lipid-lowering drug, proprotein convertase subtilisin/kexin 9 (PSCK9) inhibitors, showed a more effective reduction in EAT after 6 months of intake (~ 20%), again, independently of LDL-C [52].”
BackgroundInfluentialSalvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62 · see citing works
Elsanhoury, A., Nelki, V., Kelle, S., Van Linthout, S., & Tschöpe, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.720690 · Cited by 51 · see citing works
“concluded that 6 months of treatment with PSCK9i could achieve a 20% reduction in EAT thickness (91).”
BackgroundCardio-Lipotoxicity of Epicardial Adipose Tissue
BODENSTAB, M., Varghese, R. T., & Iacobellis, G. (2024) · Biomolecules · doi:10.3390/biom14111465 · Cited by 46 · see citing works
Epicardial Adipose Tissue in Myocardial Disease: From Physiology to Heart Failure Phenotypes
Antonopoulos, A. S., Papastamos, C., Cokkinos, D. V., Tsioufis, K. P., & Tousoulis, D. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101841 · Cited by 27 · see citing works
Shi, Y., Dong, G., & Guo, M. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.724 · Cited by 25 · see citing works
Epicardial Adipose Tissue as an Independent Cardiometabolic Risk Factor for Coronary Artery Disease
Karampetsou, N., Alexopoulos, L. G., Minia, A., Pliaka, V., Tsolakos, N., Kontzoglou, K., Perrea, D. N., & Patapis, P. (2022) · Cureus · doi:10.7759/cureus.25578 · Cited by 20 · see citing works
“observed that in 24 patients who received either evolocumab or alirocumab for six months, EAT thickness was significantly reduced as measured by transthoracic echocardiography [76].”
BackgroundEpicardial fat and ventricular arrhythmias
Załęska‐Kocięcka, M., Wojdyńska, Z., Kalisz, M., Litwiniuk, A., Ma̧czewski, M., Leszek, P., & Paterek, A. (2023) · Heart Rhythm · doi:10.1016/j.hrthm.2023.11.008 · Cited by 17 · see citing works
Epicardial fat in heart failure—Friend, foe, or bystander
Paterek, A., Załęska‐Kocięcka, M., Wojdyńska, Z., Kalisz, M., Litwiniuk, A., Leszek, P., & Ma̧czewski, M. (2024) · Obesity Reviews · doi:10.1111/obr.13820 · Cited by 16 · see citing works
“109 Nevertheless, statins do not provide clinical benefits in patients with chronic HF (either HFrEF or HFpEF).”
Qi, Z., Wu, D., Yan, Z., Wang, Q., Li, Y., Zhao, J., & Xu, F. (2025) · Obesity Reviews · doi:10.1111/obr.13912 · Cited by 13 · see citing works
“A non-randomized cohort study reported a 20.39% reduction in EAT thickness following 6 months of PCSK9 inhibitor (evolocumab or alirocumab) administration in patients 117 .”
InfluentialWhitman, J., Kozaily, E., Michos, E. D., Silverman, D. N., Fudim, M., Mentz, R. J., Tedford, R. J., & Rao, V. N. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00700-5 · Cited by 11 · see citing works
Ding, Y., Lin, F., Liu, Z., Zhou, X., & Liang, X. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26128 · Cited by 13 · see citing works
Priscilla, L., Yoo, C., Jang, S., Park, S., Lim, G., Kim, T., & Lee, D. Y. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.01.027 · Cited by 9 · see citing works
Pop, A. S. K., Dănilă, M. D., Giuchici, S., Buriman, D. G., Lolescu, B. M., Sturza, A., Muntean, D. M., & Lascu, A. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0384 · Cited by 8 · see citing works
Mihăilă, M.-D., Caloian, B., Frîngu, F. I., Irimie, D. A., Minciună, I., & Pop, D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176139 · Cited by 5 · see citing works
Epicardial Adipose Tissue: A Potential Target to Improve Left Ventricular Diastolic Dysfunction
Ran, C.-Q., & He, W. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39224 · Cited by 3 · see citing works
Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients
Gorrai, A., FARR, M. A., O’Hara, P. J., Beaini, H., HENDREN, N. S., Wrobel, C. A., Hardin, E. A., McGuire, D. K., Khera, A., Wang, T. J., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.12.006 · Cited by 3 · see citing works
Intermuscular Adipose Tissue in CKD
Demirci, M., Dilaver, R. G., Roshanravan, B., Ikizler, T. A., & Gamboa, J. L. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000745 · Cited by 4 · see citing works
The Role of Pericardial Fat in Cardiometabolic Disease: Emerging Evidence and Therapeutic Potential
Shahrori, Z., Helou, M. C. E., Sallam, S., Iacobellis, G., & Neeland, I. J. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02305-9 · Cited by 2 · see citing works
“Reductions in EAT are thought to contribute to the cardio-metabolic benefits observed after bariatric surgery, poten - tially through decreased local inflammation and reduced paracrine signaling affecting the myocardium and coronary arteries.”
Epicardial adipose tissue in coronary microvascular disease
Gašpárková, V., Tran, B. T., Ošťádal, P., Lambert, L., Hájek, P., & Kala, P. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100734 · Cited by 2 · see citing works
“Meta-analyses report a modest average reduction of ~6% with statins, whereas newer lipid-lowering agents, such as PCSK9 inhibitors, can achieve greater reductions of ~20% independent of LDL cholesterol [82,83].”
Atherosclerosis Research: Origin, Viewpoint and Development Trend
李, 晨. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125716 · Cited by 1 · see citing works
Genetic Implications of Fatty Tissue for the Development of Ventricular Arrhythmias
Prisecaru, R. S., Purcar, O., & Maniţiu, I. (2025) · Cardiogenetics · doi:10.3390/cardiogenetics15010008
“GLP-1 receptor agonists are a type of glucose-lowering drug that lowers HbA1c, and modestly improves blood lipids and body weight while decreasing the risk of hypoglycemia by stimulating insulin secretion and lowering glucagon secretion, delaying gastric emptying, and reducing appetite [116].”
Myasoedova, V. A., Parisi, V., Moschetta, D., Valerio, V., Conte, M., Massaiu, I., Bozzi, M., Celeste, F., Leosco, D., Iaccarino, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26565297
Myasoedova, V. A., Parisi, V., Moschetta, D., Valerio, V., Conte, M., Massaiu, I., Bozzi, M., Celeste, F., Leosco, D., Iaccarino, G., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26565300
Zhiyong, 王. W., Xiaoxu, 鲁. L., Fuwang, 吴. W., et al. (2026) · Chinese Journal of Lasers · doi:10.3788/cjl251548
Đuzel, A., Rotkvić, P. G., Babić, Z., Šipoš, I. H., Bekić, M., Bratičević, M. N., Rotkvić, L., & Berković, M. C. (2026) · Medicina · doi:10.3390/medicina62071402
- Authors
- Rivas Galvez, R. E., Morales Portano, J. D., Trujillo Cortes, R., Gomez Alvarez, E. B., Sanchez Cubias, S. M., & Zelaya, S. M.
- Affiliations
- National Medical Center November 20, Mexico City, Mexico
- National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico
- Ministerio de Salud (SV)
- ORCID
- Zelaya, S.M
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-01
- Volume
- 41
- Issue
- Supplement_2
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W3110151534
- Cited by
- 29
- References
- 0
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 6 · 2023: 4 · 2022: 5 · 2021: 1
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- European Heart Journal (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Cardiac Imaging and Diagnostics
- Keywords
- epicardial adipose tissue, PCSK9 inhibitors, evolocumab, alirocumab, transthoracic echocardiography, epicardial fat thickness, LDL cholesterol lowering, atherosclerosis, cardiovascular risk, myocardial infarction, lipid-lowering therapy, subcutaneous adipose tissue, visceral adipose tissue, coronary artery disease risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
